Mosanna Therapeutics is developing a small molecule, MOS-118, specifically targeting metabolic obstructive sleep apnea (MOSA) to enhance patient outcomes. The company aims to improve the quality of life for individuals suffering from this condition by addressing the underlying metabolic factors contributing to their sleep disturbances.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic obstructive sleep apnea (MOSA) significantly diminishes the quality of life for affected individuals due to sleep disturbances. Current treatments do not directly address the underlying metabolic factors contributing to the condition. This results in suboptimal patient outcomes and a continued need for more targeted therapeutic interventions.
Solution
Mosanna Therapeutics is developing MOS-118, a small molecule specifically designed to target the metabolic dysfunction associated with MOSA. This therapeutic approach aims to improve patient outcomes by directly addressing the metabolic underpinnings of the disease. By targeting these factors, MOS-118 has the potential to alleviate sleep disturbances and enhance the overall well-being of individuals suffering from MOSA. The company's focus is on providing a more effective and targeted treatment option for this prevalent condition.
Target Audience
The primary target audience includes individuals diagnosed with metabolic obstructive sleep apnea (MOSA) seeking improved treatment options.
Features
- MOS-118: A small molecule specifically targeting metabolic dysfunction in MOSA.